The discovery of 1I/Oumuamua, 2I/Borisov and 3I/ATLAS showed that significant numbers of interstellar objects populate interstellar space. Their omnipresence means that such objects also reside in protoplanetary disks, which are the reservoir…
Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X about a paper he co-authored with colleagues published in Leukemia Research:
“Applicability of current prognostication models for MDS patients with…
Uzbekistan’s Akbar Djuraev couldn’t help but crack a sly smile, as the bar went crashing down on his final attempt at the 2025 IWF World Weightlifting Championships in Førde, Norway on Friday (10 October).
The global issue of illicit drug use has worsened, with 292 million users in 2022, a 20% increase over the past decade []. Cannabis is the most widely used illicit drug (228 million), followed by opioids (60 million), cocaine (23 million), and others []. Illicit drug users face various psychological and physiological problems, including mental disorders, cognitive deficits, cardiovascular dysfunction, and blood-borne infections. The social burden is also high, due to links with crime, violence, and sexual abuse []. Treatment is urgently needed, but globally, only about 10% of users receive treatment, a decline since 2015 [].
Traditional face-to-face psychosocial treatments remain important for illicit drug users but often fail to meet the needs of most patients due to time, location, and social stigma []. The COVID-19 pandemic accelerated the development of telehealth [] and pushed digital interventions from early simple interactions to more complex forms []. Modern digital interventions can provide multiple interaction methods via smart devices, such as apps, websites, email, text messages, video, audio, and computer programs. They overcome the limitations of traditional treatments and are valued for their flexibility and cost-effectiveness [-], better meeting personalized needs and improving treatment engagement []. Meta-analyses show that digital interventions are effective across different populations of illicit drug users [-].
However, dropout rates are particularly prominent in digital interventions [-]. Meta-analyses indicate that about one-third of individuals with substance use disorders fail to complete treatment [] and only 48% of early dropouts seek help again [], significantly increasing the risk of adverse outcomes [,]. Methodologically, the relatively high dropout rate limits the completeness of research findings, affecting the validity of results and the interpretation of treatment effects []. To improve the accuracy, this study clearly distinguishes three key concepts: engagement refers to behavioral involvement during use []; adherence reflects the alignment between actual behavior and intervention expectations []; while the dropout rate in this study is strictly defined as participants leaving, being lost to follow-up, or stopping participation before the outcome assessment for any reason. This conceptual clarification both distinguishes commonly confused terms and provides a methodological basis for enhancing the effectiveness of digital interventions, with important clinical implications.
Although the dropout rate is an important outcome indicator of intervention efficacy [], few studies have examined dropout rates among illicit drug users in digital interventions. A meta-analysis published in 2017 was the first to evaluate internet-based interventions in reducing illicit substance use after treatment and follow-up, but dropout rate was not the focus []. Moreover, existing research lacks systematic examination of clinical factors and intervention design, as well as dynamic assessment of dropout patterns at different time points [-], directly limiting the optimization of targeted intervention strategies.
Based on current research, this study aims to address the gap in dropout rate research in digital interventions. The study compared average dropout rates between the digital intervention and control groups to assess treatment retention under different experimental conditions. It also analyzed how variables at posttreatment and the longest follow-up time points affected dropout rates in the intervention group to support personalized intervention design for different research stages. These findings are important for advancing academic research and expanding clinical applications [].
Methods
Protocol Registration
This study strictly adheres to the guidelines of the Cochrane Handbook for Interventions [] and is reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines [] (the complete PRISMA checklist is available in ). The research protocol has been registered in the PROSPERO system: CRD42024534389.
Search Strategy
To comprehensively and systematically collect relevant literature, this study searched five major databases up to August 27, 2025, including Web of Science, PubMed, PsycINFO, Embase, and the Cochrane Controlled Trials Register. The search strategy combined controlled vocabulary (eg, MeSH terms) and free-text keywords using Boolean operators (“AND” and “OR”). The main search terms included the following: (“digital intervention” OR “internet intervention” OR “e-health” OR “m-health”) AND (“drug abuse” OR “substance use disorder” OR “illicit drugs”) AND (“psychotherapy” OR “psychoeducation” OR “psychodynamic”) AND (“randomized controlled trial” OR “single blind procedure” OR “random sample”). The complete search strategy for each database is provided in .
Inclusion and Exclusion Criteria
Inclusion criteria were as follows: (1) Individuals aged 18 years and above with illicit drug use behavior. Illicit drugs refer to controlled substances used for nonmedical or nonscientific purposes, including but not limited to cannabis, cocaine, amphetamines, and opioids []. (2) Digital psychosocial intervention is the primary treatment. Operationally defined as structured psychological intervention primarily delivered through digital platforms, including mobile applications, web-based programs, or digital communication tools, with or without minimal human support. (3) The article must report sample size and dropout rates. (4) Randomized controlled trials. Exclusion criteria were as follows: (1) treatment involving only face-to-face therapy. (2) mixed samples with insufficient proportion of illicit drug users (less than 80%) or without independent subgroup data (eg, alcohol and tobacco users). (3) non-English studies. (4) unpublished reports, study protocols, meta-analyses, reviews, doctoral theses, or other gray literature.
To ensure the accuracy of literature screening, a dual-screening process was adopted. First, two researchers independently screened the titles and abstracts of retrieved literature to exclude those clearly not meeting inclusion criteria. Subsequently, the full texts of the literature were reviewed for further evaluation. Finally, manual searches were conducted on the reference lists of included studies and related reviews to identify additional studies meeting inclusion criteria. Any disagreements were resolved through discussion.
Select Variables and Data Extraction
Outcome Variable
This study uses the dropout rate from randomized controlled trials as the primary outcome measure. Considering that the influencing factors at different treatment stages may vary [,-], the dropout rate data of the intervention and control groups at the end of treatment and at the longest follow-up time were extracted separately.
Moderator Variables
Previous studies have explored the factors influencing dropout among illegal drug users [], but due to differences in confounding variable control methods and insufficient understanding of the complexity of predictive factors, the results have been inconsistent []. Withdrawal from treatment is a dynamic process, and its mechanisms involve complex interactions of multiple factors []. It is difficult to fully explain the complexity of single-variable analysis []. Therefore, this study refers to previous research [] and selects multidimensional variables (): (1) Demographic characteristics of participants: most studies emphasize the role of patient-related variables in predicting dropout [,], and investigating individual differences (such as age, gender, race, digital literacy, etc.) is crucial for developing treatment interventions for specific populations [16]. (2) Baseline clinical characteristics of participants, including the type of illegal drug use, medication patterns, frequency of use, duration of use, and comorbid conditions. Different drugs may have differentiated effects on dropout rates due to their unique pharmacological mechanisms and withdrawal characteristics []. Additionally, the presence of comorbid mental disorders may exacerbate the likelihood of treatment interruption [], which also needs to be considered. (3) Therapist characteristics: the therapeutic orientation and experience level of therapists may be related to patient adherence []. Compared to busy clinic staff, full-time therapists are more likely to invest time and effort to retain and reengage patients who have discontinued treatment [32]. (4) Treatment characteristics: referring to the framework proposed by Derubeis et al [], which focuses on all factors that improve treatment and particularly on the relationship between treatment factors and outcomes. For example, this study extracted personalized feedback, real-time interaction, and therapeutic alliance. The optimization of these modifiable operational variables can directly enhance intervention effectiveness and improve patient treatment adherence [].
Table 1. Predictor variables.
Predictor category
Variable category
Variable
Data note
Demographic characteristics of participants
Continuous variable
Year
Publication year
N
Number of participants
Age
Mean years
Female
Percentage
White
Percentage
African American
Percentage
Education
≦High school degree (%)
Employed
Percentage
Unemployed
Percentage
Single/never married
Percentage
Currently single
Percentage
Married/living together
Percentage
Classified variable
Developed country
Y, N
Low income
Y, NR
Baseline clinical characteristics of participants
Continuous variable
Diagnostic
Percentage
Use quantity-pre
Mean percentage of substance use quantity in the past 30 days
Use frequency-pre
Mean percentage of substance use frequency in the past 30 days
Use length-pre
Mean length of substance use in years at intake
Abstinence
Percentage
Classified variable
Inclusion criteria
Diagnostic and Statistical Manual (DSM) diagnosis, Other
Comorbid HIV
Y, N
Primary drug use
Cocaine, Opioids, Cannabis, ATS, Other
Therapist characteristics
Classified variable
Master
Y, NR
Relevant experience
Y, NR
Train
Y, NR
Supervision
Y, NR
Treatment characteristics
Continuous variable
Session
Number of weekly sessions
Intervention duration
Number of weeks
The longest follow-up
Number of weeks
Classified variable
Recruitment
Website, Clinic, Community, Campus, Multiple
Compensation mode
Gift certificate, USD
Compensation
Stepped, NR
Measurement
Self-report, Toxicology, Both
Toxicology
Y, N
Guidance
Guided, Unguided
Personalized feedback/intervention
Y, NR
Real-time interaction
Y, NR
Setting
Anywhere, Laboratory
Delivery
Computer, Telephone
Digital media
App, Website
Digital presentation mode
Video, Virtual character
Fully digital
Y, N, NR
Assessing digital quality
Y, NR
aN: Number.
b“Employed” and “Unemployed”: Not complementary, they were extracted separately from different studies. We extracted only based on the study reports and did not perform back-extrapolation calculations.
cDeveloped country: According to the World Health Organization.
dY: Yes.
eN: No.
fNR: Not reported.
gATS: Amphetamine-type stimulants.
hUSD: Use USD as experimental compensation.
iCompensation: Refers to the monetary or nonmonetary rewards provided to study participants for their time and effort.
jStepped: Refers to a structured payment approach where participants receive partial rewards at different stages (eg, time-based or task-completion).
Data Extraction
Two researchers independently extracted data using a predesigned data extraction form. Disagreements were resolved through discussion or consultation with a third researcher. This data extraction form has been piloted in some studies and adjusted according to the recommendations and structured framework of the GRADE manual. For articles that met the inclusion criteria but lacked important data, we contacted the corresponding author via email, and studies that could not provide sufficient data to calculate effect sizes were excluded.
Quality Assessment
To assess the bias risk of the included studies, two researchers independently scored each study in five aspects using the revised Cochrane Risk of Bias tool ROB 2.0 []: randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result. Any disagreements were resolved through discussion.
Statistical Analysis and Software
We used Comprehensive Meta-Analysis software (CMA 4.0) to synthesize dropout rates across studies []. For each trial, dropout counts and total sample sizes were extracted separately for the intervention and control groups, from which group-specific dropout proportions were calculated. To stabilize variances and account for the bounded nature of proportions, these proportions were transformed into logit event rates with corresponding standard errors, which served as the primary effect size metric. Pooled estimates were calculated separately for intervention and control groups and subsequently back-transformed into raw proportions and expressed as percentages for interpretability, an approach that has been widely applied in meta-analyses of proportion-type outcomes []. Subsequently, between-study heterogeneity was examined using the Q statistic [,] and quantified with the I² statistic []. Given the significant heterogeneity among included studies in outcome measures and moderators [,], all analyses were conducted under a random-effects model []. Publication bias was assessed using funnel plots, Egger’s, Duval and Tweedie’s trim and fill, and Classic fail-safe N tests [], while sensitivity analyses were conducted to evaluate the robustness of the results. To explore potential influencing factors, meta-regression and subgroup analyses were further employed to examine the association between moderators in the intervention group and dropout rate.
Results
Characteristics of the Included Studies
After screening relevant articles based on predefined inclusion and exclusion criteria, a total of 41 studies were finally included (see ), involving 9693 participants with an age range of 19 to 50 years. The selection characteristics of the included studies are shown in . The studies included 82 intervention groups, with a total of 48 dropout rate data points, including 18 posttreatment dropout rates and 30 follow-up dropout rates, showing different data results between the two measurement points.
Figure 1. PRISMA flow diagram of study search and selection. DPI: Digital psychosocial intervention; PRISMA: Preferred Reporting Items for Systematic reviews and Meta-Analyses; RCT: randomized controlled trial.
Table 2. Selected characteristics of included studies.
Author (year)
Country
N
Recruitment
Primary substance
Intervention type
Age, M (SD)
F (%)
Intervention duration (wk)
Sessions
The longest follow-up (wk)
Aharonovich (2012)[]
USA
40
Clinic
Cocaine/crack (75.8%)
MI+BI
45.5 (6.6)
24.2
8
7.00
NR
Aharonovich (2017a)[]
USA
240
Clinic
Any
MI+BI
46.5 (9.3)
16.3
8.57
7.00
48
Aharonovich (2017b)[]
USA
47
Multiple
Crack (91.49%)
MI+BI
50.9 (7.0)
23.4
8.57
7.00
NR
Baumgartner (2021)[]
Switzerland, Austria, Germany, Other (0.7%)
575
Website
Cannabis (100%)
CBT+MI+BI
28.3 (7.9)
29.4
6
NR
12
Blow (2017)[]
USA
780
Clinic
Cannabis (91.1%)
MI
31.2 (10.9)
55.5
1
1.00
12
Bonar (2022)[]
USA
149
Website
Cannabis (100%)
CBT+MI
21 (2.2)
55.7
8
7.00
24
Bonar (2023)[]
USA
58
Clinic
Cannabis (100%)
MI
21.5 (2.4)
65.5
4
7.00
12
Brooks (2010)[]
USA
28
Clinic
Cocaine
CRA
43.1 (9.2)
55
8
3.00
10
Buckner (2020)[]
USA
63
Campus
cannabis
BI
19.1 (1.5)
84.1
64
1
2
Budney (2011)[]
USA
38
Community
Cannabis (100%)
MET+ CBT+CM
32.8 (9.7)
47.1
12
1.00
NR
Budney (2015)[]
USA
75
Multiple
Cannabis (100%)
MET+ CBT+CM
35.9 (10.5)
43
12
2.00
36
Campbell (2014)[]
USA
507
Clinic
Any
CRA+CM
34.9 (10.9)
37.9
12
4.00
24
Carroll (2014)[]
USA
101
Clinic
Cocaine (100%)
CBT
41.9 (9.6)
60.4
8
7.00
24
Chopra (2009)[]
USA
120
Community
Opioid (100%)
CRA+CM
31.8 (10.5)
42.5
12
3.00
NR
Christensen (2014)[]
USA
170
Multiple
Opioid (100%)
CRA+CM
34.3 (10.8)
45.9
12
3.00
NR
Christoff (2015)[]
Brazil
458
Campus
Any
MI
24 (5.4)
7
0.14
1.00
12
Chun-Hung (2023)[]
Taiwan, China
99
Clinic
ATS (100%)
MBRP
37 (10.4)
18.2
NR
4.20
24
Conner (2024)[]
Canada, USA
781
Campus
Cannabis
BI
21.7 (2.8)
39.7
0.14
1
4
Coronado-Montoya (2025)[]
Canada
101
Clinic
Cannabis (100%)
CBT+MI
25.2 (3.9)
18.8
6
1
18
Dunn (2017)[]
USA
76
Clinic
Opioid (100%)
PE
39.9 (12.7)
40.8
1
1.00
12
Elliott (2014)[]
USA
162
Campus
Cannabis (100%)
PE
19.3 (1.2)
52
NR
NR
4
Glasner (2022)[]
USA
54
Multiple
Opioid (50%), ATS (50%)
CBT
47.7 (8.2)
20
12
7.00
NR
Gryczynski (2015)[]
USA
360
Clinic
Any
MI
36.2 (14.6)
46
NR
NR
48
Gryczynski (2016)[]
USA
80
Community
Any
MI
35 (13)
53
1
1.00
24
Gustafson (2024)[]
USA
414
Clinic
Opioid
PE+BI+MI
37.2 (10.0)
45.2
64
NR
32
Ingersoll (2011)[]
USA
56
Community
Crack cocaine (100%)
PE
45 (6.4)
51.9
8
0.75
24
Maricich (2021)[]
USA
170
Multiple
Opioid (100%)
CRA
32.9 (9.8)
45.9
12
2.50
NR
Marsch (2014)[]
USA
160
Community
Opioid (100%)
CRA+CBT
40.7 (9.8)
25
48
0.54
NR
Moore (2019)[]
USA
82
Clinic
Any
CBT
42.4 (10.9)
40.2
12
7.00
12
Olthof (2023)[]
Netherlands
378
Website
Cannabis (100%)
CBT+MI
27.5 (8.5)
30.7
NR
NR
24
Ondersma (2007)[]
USA
107
Clinic
Any
MI
25.1 (5.6)
100
1
1.00
24
Ondersma (2014)[]
USA
143
Clinic
Any
MI
26.6 (6)
100.0
1
1.00
24
Schaub (2019)[]
Switzerland
311
Website
Cannabis (100%)
PE+CBT+MI
33.1 (7.6)
27
6
1.50
24
Schaub (2015)[]
Switzerland
308
Multiple
Cannabis (100%)
CBT+MI
29.8 (10)
24.7
6
NR
12
Schwartz (2014)[]
USA
360
Community
Cannabis (88%)
BI
36.1 (14.6)
46
1
1.00
12
Shi (2019)[]
USA
20
Community
Opioid (100%)
CBT
40.5 (12.2)
40
12
6.88
NR
Sinadinovic (2020)[]
Sweden
303
Website
Cannabis (100%)
PE+CBT+MI
27.4 (7.2)
32.7
6
1.50
12
Tait (2015)[]
Australia
160
Multiple
ATS (100%)
CBT+MI
22.4 (6.3)
24
NR
NR
24
Tossmann (2011)[]
Germany
1292
Website
Cannabis (100%)
SFBT
24.7 (6.8)
29.5
7.14
NR
12
Walukevich-Dienst (2019)[]
USA
227
Campus
Cannabis (100%)
PE
19.8 (1.4)
77
NR
NR
4
Xu (2021)[]
China
40
Community
ATS (>90%)
PE+ST
46.1 (9.9)
22.5
NR
1.00
24
aN: Number of participants.
bMI: Motivational interviewing.
cBI: Brief intervention.
dNR: Not reported.
eCBT: Cognitive behavior therapy.
fCRA: Community reinforcement approach.
gMET: Motivational enhancement therapy.
hCM: Contingency management.
iATS: Amphetamine-type stimulants.
jMBRP: Mindfulness-based relapse prevention.
kPE: Psychoeducation.
lSFBT: Solution-focused brief therapy.
mST: Support.
Risk of Bias Assessment
The risk of bias in the included studies was assessed using the Cochrane Risk of Bias tool (ROB 2.0). Detailed results and percentage plots are presented in . The results showed that approximately 90% of the included studies had a low risk in terms of the randomization process (D1), measurement of the outcome (D4), and selection of the reported result (D5). Approximately 55% of the included studies had some concerns about deviations from intended intervention (D2). About 50% of the studies had a high risk of missing outcome data (D3), which is a key focus of our research.
Meta-Analysis Results
Posttreatment
An analysis of 18 studies was conducted using a random-effects model. The main effect results () showed that the mean dropout rate in the intervention group was 22% (95% CI 0.13‐0.36), lower than that in the control group of 26% (95% CI 0.16‐0.39) []. However, heterogeneity testing indicated high variability among the studies (Q=396.18, df=17, P<.001; I²=96%). Further analysis revealed that the variance of the true effect size reached 2.02 (logit units) with a standard deviation of 1.42 (logit units).
Figure 2. Forest plot of dropout rate in the intervention group at posttreatment [-,,-,,,-,,].
Meta-regression and subgroup analysis revealed that this extreme variability was primarily due to four variables among three categories (): (1) Participant demographic characteristics: The proportion with employment rate showed a weak positive correlation with dropout rate (OR 1.04, 95% CI 1.00‐1.07; P=.03). (2) Participant clinical characteristics: Participants with baseline clinical diagnoses showed a significant positive correlation with dropout rate (odds ratio [OR] 1.03, 95% CI 1.01‐1.06; P=.01). The dropout rate for those using cocaine as the baseline primary medication (OR 1.96, 95% CI 0.31‐12.57; P=.48) was significantly higher than that for those using cannabis and opioid medications. (3) Intervention characteristics: Intervention frequency showed a significant negative correlation with dropout rate (OR 0.77, 95% CI 0.60‐0.99; P=.04). The other 27 factors showed no significant correlation with dropout rate.
Table 3. Meta-regressions and subgroup analysis in the intervention group at posttreatment.
Predictor category
Predictor/Predictor value
Studies
Coefficient
Standard error
Dropout (95% CI)
z-value
2-sided P value
Demographic characteristics of participants
Employed
6
0.0348
0.0159
0.0036 to 0.0661
2.19
.0288
Baseline clinical characteristics of participants
Diagnostic
12
0.0305
0.0125
0.0060 to 0.0549
2.44
.0145
Primary drug use
17
.0190
Cocaine
3
0.6738
0.9478
−1.1838 to 2.5314
0.71
.4771
Opioid
5
−0.2639
0.8303
−1.8912 to 1.3634
−0.32
.7506
Cannabis
5
−0.7448
0.5838
−1.8889 to 0.3994
−1.28
.2020
Other
4
−2.2799
0.9056
−4.0548 to −0.5050
−2.52
.0118
Treatment characteristics
Session
17
−0.2609
0.1266
-0.5090 to −0.0127
−2.06
.0394
The funnel plot showed some studies beyond the expected range (), suggesting the presence of studies with extreme dropout rates. Combined with Egger’s test results (P<.001), this further confirmed the presence of publication bias. After trimming the 5 missing studies on the right side, the effect size was adjusted from 22% to 33%, still not crossing the clinical threshold. Further leave-one-out analysis showed that 366 unpublished studies would need to be included to make the current result statistically insignificant. Overall, the results indicate that despite publication bias, the adjusted effect size did not exceed the clinical threshold and the leave-one-out number was high, supporting the stability of the study conclusions. Sensitivity analysis also showed () that removing any single study would not change the overall trend.
Figure 3. The funnel plot for dropout rate in the intervention group at posttreatment. Figure 4. Sensitivity analysis for dropout rate in the intervention group at posttreatment [-,,-,,,-,,].
The Longest Follow-Up
Follow-up analysis of the intervention group was based on 30 studies, with an average dropout rate of 28.2% (95% CI 0.19‐0.39) (), while the rate in the control group was 27.8% (95% CI 0.20‐0.37). However, heterogeneity testing again indicated high variability among the studies (Q=1293.13, df=29, P=.000, I²=98%). Further analysis revealed that the variance of the true effect size reached 1.79 (logit units) with a standard deviation of 1.34 (logit units).
Figure 5. Forest plot of dropout rate in the intervention group at the longest follow-up [,,-,,,-,-,-,-].
Meta-regression analysis and subgroup analysis () revealed that this extreme variability is primarily due to 4 variables among three types of characteristics: (1) participant characteristics: dropout rate showed a negative correlation with single status (OR 0.95, 95% CI 0.91‐0.99; P=.01); (2) clinical characteristics: significantly positive correlation with baseline medication frequency (OR 1.18, 95% CI 1.05‐1.32; P=.004); (3) intervention characteristics: participants recruited via website showed a positive correlation with dropout rate (OR 5.74, 95% CI 1.85‐17.76; P=.002), while participants recruited via campus showed a negative correlation with dropout rate (OR 0.28, 95% CI 0.12‐0.66; P=.003); The association between the degree of digitalization and dropout rates varied depending on whether studies with unreported digitalization status (not reported [NR] group) were included. When all studies, including the NR group, were analyzed, the overall model reached statistical significance (Q=28.13, df=2, P<.001), with the NR group showing a strongly significant negative effect (OR 0.16, 95% CI 0.06‐0.41; P<.001). However, when the NR group was excluded and only studies explicitly reporting “fully digital” or “partially digital” were considered, the results were not statistically significant (Q=0.24, P=.62). The other 32 factors showed no significant correlation with dropout rate.
Table 4. Meta-regression and subgroup analysis in the intervention group at the longest follow-up.
Predictor category
Predictor/Predictor value
Studies
Coefficient
Standard error
Dropout (95% CI)
z-value
2-sided P value
Demographic characteristics of participants
Currently single
10
−0.0528
0.0214
−0.0947 to −0.0108
−2.47
.0136
Baseline clinical characteristics of participants
Use frequency-pre
10
0.1657
0.0576
0.0528 to 0.2786
2.88
.0040
Treatment characteristics
Recruitment
28
Website
6
1.7478
0.5762
0.6168 to 2.8770
3.03
.0024
Clinic
12
0.0973
0.5204
−0.9225 to 1.1172
0.19
.8516
Campus
5
−1.2797
0.4371
−2.1365 to −0.4230
−2.93
.0034
Community
5
−0.8413
0.6384
−2.0924 to 0.4099
−1.32
.1875
Fully digital
30
No
4
0.5442
0.4530
−0.3437 to 1.4320
1.20
.2297
Yes
3
0.2858
0.6540
−0.9960 to 1.5676
0.44
.6621
Not reported
23
−1.8401
0.4882
−2.7970 to −0.8831
−3.77
.0002
The funnel plot showed some studies beyond the expected range (see ). Combined with Egger test results (P=.023), publication bias was further confirmed. After trimming the six missing studies on the right side, the effect size changed from 28% to 37% after correction, without crossing the clinical threshold. Further leave-one-out sensitivity analysis showed that 1244 unpublished studies would need to be included to make the current results statistically insignificant, supporting the stability of the research conclusion. Meanwhile, sensitivity analysis (see ) indicated that the results of this study were robust and not dependent on individual studies.
Figure 6. The funnel plot for dropout rate in the intervention group at the longest follow-up. Figure 7. Sensitivity analysis for dropout rate in the intervention group at the longest follow-up [,,-,,,-,-,-,-].
Discussion
Principal Findings
This meta-analysis systematically evaluated the treatment retention effect of digital psychosocial interventions among adult illicit drug users. The pooled dropout rate was 22%, slightly lower than the approximately 30% reported for face-to-face psychosocial interventions [], suggesting potential advantages of digital formats for treatment retention. Nevertheless, the substantial heterogeneity across studies limits the generalizability of these findings. Dropout rates also varied across settings and populations. For instance, adults with co-occurring severe mental disorders and substance use had an average dropout of 27% [], whereas clinical samples of opioid users showed rates as high as 41% []. Beyond dropout, adherence constitutes another key indicator of engagement, with evidence showing that participants completed, on average, 60% of digital intervention modules, and only about half finished the full program []. Taken together, these results underscore the importance of considering both dropout and adherence when evaluating intervention effectiveness. Building on this, our moderator analyses further revealed complex interactive effects. To ensure clarity, we retained the classification system established during data extraction, presenting results separately across four major categories of characteristics as well as between short-term and longest intervention stages.
At the posttreatment stage, dropout was significantly influenced by participants’ demographic, intervention, and clinical characteristics. Regarding demographics, unemployment did not predict dropout, whereas higher employment was unexpectedly associated with greater attrition. This suggests that unstable or high-intensity work may interfere with regular participation. In addition, the short-term income from employment may reduce some patients’ motivation for treatment, especially when symptoms temporarily improve, leading them to discontinue prematurely due to “feeling better” []. For intervention characteristics, intervention frequency showed a negative correlation with dropout, indicating that more frequent contact may help consolidate behavior change, strengthen the therapeutic alliance, and enhance commitment [-]. Future studies should explore the optimal intervention frequency under different conditions [], balancing treatment intensity with patient burden [].
The results of baseline clinical characteristics indicated that both baseline clinical diagnosis and baseline cocaine use were significantly positively associated with dropout rates. Specifically, patients with a clear baseline diagnosis were at greater risk of dropout due to challenges such as dependency, withdrawal symptoms, and impaired cognitive or emotional functioning []. For this population, the integration of adjunctive pharmacological or behavioral therapies is recommended to reduce dropout []. Furthermore, consistent with previous findings [], participants with baseline cocaine use were more likely to discontinue treatment. Cocaine use disorder is often closely linked to impulsive behavior and diminished adherence []. These substance-specific risks highlight the importance of developing differentiated intervention strategies tailored to distinct types of substance use in future research []. Nevertheless, the small sample size of drug-use subgroups (k≤5) remains a limitation, which could be addressed through multi-institutional collaborations to expand subgroup samples.
During the longest follow-up, dropout was significantly influenced by demographic, clinical, and intervention characteristics. In demographics, a higher proportion of single participants was linked to lower dropout. This may be related to reduced drug exposure in family environments [-]. In addition, single participants with low social support were more likely to continue seeking health information online. Future research could involve non–drug-using significant others in monitoring the intervention process and integrate peer support modules []. In clinical characteristics, participants with higher baseline drug use frequency faced markedly greater dropout risk. This finding is consistent with recent studies []. For this high-risk group, we recommend the implementation of multistage intensive intervention programs [], together with the development of immediate-response modules (eg, crisis management tools, real-time consultation functions) to reduce early dropout [].
In terms of intervention characteristics, participants recruited through websites exhibited higher dropout rates, whereas those recruited from campus showed lower dropout rates. This may be explained by the lack of intensive treatment services typically provided in clinical settings, as well as the relative stability of campus environments [,]. Based on this finding, we recommend adopting a mixed online–offline recruitment strategy []. In addition, intervention content should be optimized for online recruits [], including simplifying operational procedures, providing regular reminders, and offering personalized feedback. The study also analyzed the association between the degree of digitalization and dropout rates. During data processing, studies that did not report their digitalization status (23/30, 77%) were categorized separately as a “Not reported” group for analysis rather than being directly excluded. The analysis revealed a significant association: compared to the nonsignificant negative correlation between fully digital interventions and dropout rates, interventions with unreported digitalization status showed a significant negative correlation, while non-fully digital interventions demonstrated a significant positive correlation with dropout rates. However, the reliability of these subgroup comparisons is constrained by the prevalent issue of poorly reported data. When we excluded the “Not reported” studies and repeated the analysis, no significant differences were found between fully digital and partially digital interventions. This suggests that the initial findings were likely confounded by nonrandom reporting bias rather than reflecting true effects, making definitive evaluation difficult. Therefore, these results primarily highlight the urgent need for future research to standardize the reporting of specific digital intervention details in order to more reliably explore the role of digitalization degree and human support in improving retention rates [].
Research Significance
This study systematically evaluated the dropout rate and its predictive factors among adult illicit drug users in digital psychological interventions, thereby addressing a critical research gap in the field. Unlike previous studies that primarily focused on demographic characteristics, this analysis incorporated multidimensional predictive variables—including clinical features, therapist-related factors, and intervention characteristics—to establish a more systematic theoretical framework. The identification of eight key predictive factors provides valuable insights for personalized interventions, guiding the development of tailored digital tools for patients at high risk of dropout. Optimization strategies derived from this evidence are expected to substantially reduce dropout rates and enhance intervention effectiveness [].
Limitations and Future Research
This study has several limitations. First, few of the included trials provided detailed information on software quality or reasons for dropout, which limited our ability to assess the reasons why participants stopped treatment []. Future studies could combine machine learning methods to predict dropout risk [] and use participant-centered questionnaires to collect data on perceived barriers. Previous research [-] emphasized common reasons for dropout, including technical difficulties, lack of engagement, and perceived ineffectiveness of the intervention. Collaboration with software engineers may help optimize the digital experience and reduce technical-related attrition []. Additionally, methodological improvements, such as combining intention-to-treat analysis with run-in phase dropout screening [,], may provide more refined methods for managing early dropout.
Second, most of the digital interventions included in the studies adopted limited forms, such as videos, virtual characters, or text messages, and lacked interactive features. Incorporating gamification elements may enhance user engagement [], especially when personalized to individual preferences [,]. Emerging evidence suggests that well-designed therapeutic video games can improve cognitive and mental health outcomes [], even inducing neurobiological changes, including alterations in white matter microstructure [-].
Finally, many studies did not clearly report key methodological details, such as the degree of digitalization or level of human support. Although we conducted analyses including and excluding the “Not reported” category, the lack of such information led to inconsistent findings, preventing definitive conclusions regarding the impact of digitalization on dropout rates. Future studies should standardize reporting of intervention details, including digitalization and human support, to better understand active components and optimize strategies [,]. Another limitation is the high heterogeneity in the meta-analysis (I²>90%), which may reduce robustness. Despite sensitivity and moderator analyses, some variability remained unexplained, suggesting pooled effects may not apply equally across interventions, populations, or outcomes. Future research should adopt rigorous methodologies, including detailed reporting, preregistration, data sharing, and large-scale RCTs. Individual participant data meta-analyses can further clarify subgroup effects and sources of heterogeneity, improving generalizability [].
Conclusion
In summary, this meta-analysis systematically examined dropout rates and their predictive factors in digital psychosocial interventions for adult illicit drug users, aiming to provide a comprehensive picture of the research landscape in this field. The results indicate that both short-term and long-term adherence to interventions are characterized by considerable complexity. In the short term, dropout rates were primarily associated with employment status, baseline clinical diagnoses, baseline primary substance use, and intervention frequency. Over longer follow-up periods, marital status, baseline drug use frequency, and recruitment source emerged as key predictors. These findings suggest the need for further investigation into factors that contradict common assumptions or remain insufficiently reported in the literature, as well as greater standardization in the design, measurement, and reporting of randomized controlled trials to improve research quality. Moreover, more attention should be given to tailoring interventions for specific populations, particularly through the design of intervention functions and modules. Continued exploration in these areas will contribute to better supporting patients’ long-term recovery.
This work was funded by the Major Program of the National Social Science Foundation of China, under Grant No. 22&ZD187.
None declared.
Edited by Yan Zhuang; submitted 21.May.2025; peer-reviewed by Chekwube Obianyo, Mohammad Eghbal Heidari, Oluwadotun Catherine Balogun, Jong Long Guo; final revised version received 12.Sep.2025; accepted 19.Sep.2025; published 10.Oct.2025.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research (ISSN 1438-8871), is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.
AstraZeneca today announces a historic agreement with President Donald J. Trump’s administration to lower the cost of prescription medicines for American patients while preserving America’s cutting-edge biopharmaceutical innovation.
At a landmark event at the White House, AstraZeneca CEO Pascal Soriot joined President Trump and members of his Administration to confirm the Company voluntarily met all requests set out in the President’s 31 July letter. The Company agrees to a range of measures which will enable American patients to access medicines at prices that are equalized with those available in wealthy countries.
As part of the agreement, AstraZeneca will provide Direct-to-Consumer (DTC) sales to eligible patients with prescriptions for chronic diseases at a discount of up to 80% off list prices. AstraZeneca will participate in the TrumpRx.gov direct purchasing platform, which will allow patients to purchase medicines at a reduced cash price from AstraZeneca.
AstraZeneca has also reached an agreement with the US Department of Commerce to delay Section 232 tariffs for three years, enabling the Company to fully onshore medicines manufacturing so that all of its medicines sold in America are made in America. This will be achieved through the Company’s recently announced $50 billion investment in US medicines manufacturing and R&D over the next five years to help deliver $80 billion in Total Revenue by 2030, 50% of which is expected to be generated in the US.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Every year AstraZeneca treats millions of Americans living with cancer and chronic diseases and, as a result of today’s agreement, many patients will access life-changing medicines at lower prices. This new approach also helps safeguard America’s pioneering role as a global powerhouse in innovation and developing the next generation of medicines. It is now essential other wealthy countries step up their contribution to fund innovation.”
AstraZeneca’s commitment to the US and American patients is further reflected in the Company’s largest single investment in a manufacturing facility to date, where the Company broke ground yesterday in Virginia. This facility will support AstraZeneca’s weight management and metabolic portfolio and our leading antibody drug conjugate cancer pipeline. Additionally, a newly expanded manufacturing facility in Coppell, Texas, will officially open next week. Looking ahead, AstraZeneca will open a cell therapy manufacturing facility in Rockville, Maryland early next year and its second major R&D centre in Cambridge, Massachusetts will open in late 2026.
The US is AstraZeneca’s largest market by sales and is also home to 19 R&D, manufacturing and commercial sites. The Company’s US workforce exceeds more than 25,000 people and supports more than 100,000 jobs overall across the country. In 2025, AstraZeneca created approximately $20 billion of overall value to the American economy.
Notes
AstraZeneca’s agreement with US Government This is the second agreement that a pharmaceutical company has made with the US Department of Health and Human Services to lower the cost of medicines for American patients in the past two weeks. Specific terms of this agreement remain confidential.
AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. The contents of AstraZeneca’s website do not form part of this document and no one should rely on such websites or the contents thereof in reading this document.
Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
An experimental gene therapy from Sarepta Therapeutics increased levels of the gene missing in an ultra-rare form of muscular dystrophy, according to data the company presented Friday.
The company has said it plans to file for approval in the disease, known as limb-girdle muscular dystrophy (LGMD) 2E. That would make it the first approved treatment in LGMD, a broad collection of highly rare diseases that can deprive patients of the ability to walk and in some cases shorten life. But it is likely to face a significant uphill battle.
The LGMD 2E therapy relies on the same gene-ferrying virus that Sarepta uses in its other treatments, including its approved gene therapy for Duchenne muscular dystrophy, Elevidys, and experimental gene therapies for several other LGMD subtypes.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Tech giant Nvidia is the world’s leading artificial-intelligence chipmaker, but the company’s success has also put it in the crossfire of trade tensions.
The Santa Clara, California-based company, which is approaching a market capitalization of $5 trillion, has seen rapid growthdue to its chips, which are predominantly used to power massive data centers used by other tech firms, like OpenAI, the creator of popular AI chatbot ChatGPT.
But Nvidia’s leading technology has been used as a negotiating tool in President Donald Trump’s trade spat with China, which was kickstarted by Trump’s sweeping tariffs in April and has escalated over rare earth mineral disputes.
It’s further complicated Nvidia’s relationship with China, where it was doing roughly 25% of its graphics processing unit sales, estimates Gil Luria, head of technology research at D.A. Davidson.Nvidia’s popularity has also embroiled the company in a steep controversy for potentially allowing China to skirt around export restrictions as trade tensions continue.
“Nvidia has gotten caught in the middle of two very important things: a trade dispute between China and the United States … but more importantly, AI has become a matter of national security,” Luria said.
Nvidia CEO Jensen Huang has argued that restricting sales of American AI chips will ultimately enable Chinese developers to create their own alternatives.
Huang, 62, was born in Taiwan, and at age 9 was sent by his parents to live in Tacoma, Washington. In 1993, the Oregon State and Stanford University grad co-founded Nvidia, which started as a graphics-based processing company.
Huang — who is worth $167 billion, according to the Bloomberg Billionaires Index — has been treated as a rockstar in Taiwan for his success in the AI chips race, and previously worked as a microprocessor designer at now-competitor AMD.
“It’s really unusual to have somebody who can go from starting what was at the time a very small tech startup and throw it to the extraordinary level of success that Nvidia has grown to,” John Villasenor, a nonresident senior fellow at Brookings Institution and professor at the University of California, Los Angeles, said of Huang.
Nvidia powers the data centers that support AI technology and has been the go-to provider of those chips.
Nvidia essentially created the architecture for anyone who develops AI, leading to a surge in demand for its technology, according to Arun Sundararajan, a professor of technology, operations and statistics at NYU Stern School of Business.
The company said in September that it would invest up to $100 billion in OpenAI and provide it with data center chips as soon as late 2026.
Nvidia is competing with AMD for deals with partners like OpenAI, which said Monday it would use 6 gigawatts of AMD chips to power OpenAI’s data centers.
“The competition has undeniably arrived. Customers will choose the best technology stack for running the world’s most popular commercial applications and open-source models. We’ll continue to work to earn the trust and support of mainstream developers everywhere,” an Nvidia spokesperson said in a statement shared with CNN.
In recent years, the US government has sought to restrict Chinese access to American technology to slow Beijing’s progress on AI, thus allowing the United States to take the lead. Trump continued the trend in April, when he restricted China’s access to chips, including Nvidia’s H20, as part of his trade war.
Such restrictions on the sale of chips offended China, Luria said, and ultimately led to Beijing limiting the purchase of chips to their companies.
But the White House recently reversed their position.
“You want to sell the Chinese enough that their developers get addicted to the American technology stack,” Commerce Secretary Howard Lutnick said in July.
Trump in August greenlit sales of chips to China in an agreement with US chipmakers. Nvidia and AMD, Trump said, would give 15% of revenue from China sales to the US in exchange for export licenses. That includes giving China access to Nvidia’s H20 chips, which were released in 2024 to maintain access to the Chinese market following strict export controls.
But Beijing seemed unimpressed and trade tensions have only escalated since the start of a tit-for-tat trade war in April.
China has since increased import restrictions on US chips, including Nvidia’s processors. Trump said Friday on Truth Social that he would impose a 100% tariff on China “over and above any Tariff they are currently paying” beginning November 1 over export controls on rare earth minerals.
“Where this all gets resolved is unclear,” Luria said, because China believes “that stopping the sale of Nvidia chips into China creates some leverage on the US in the negotiation.”
Commerce Department officials are investigating whether Nvidia’s customer, Singapore-based Megaspeed, is helping China sidestep export restrictions for access to Nvidia’s tech, according to a report from the New York Times. CNN has not independently verified the Times’ reporting.
Nvidia did not respond to CNN’s request for comment.
And Nvidia’s H20 chips are widely believed to have contributed to DeepSeek, an advanced Chinese AI model that shook Silicon Valley upon its release earlier this year, raising concerns that China was further ahead on AI than previously understood.
China could also gain access to the chips on the black market, since another country could buy Nvidia’s chips and resell them to China, Sundararajan said.
“The bigger issue is if we push harder to restrict global access to Nvidia’s products, can that be counterproductive? Because it forces these countries to speed up their own pace of innovation,” Sundararajan said.